147 related articles for article (PubMed ID: 38147153)
1. Transarterial Chemoembolization Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma (IDADOX): Protocol for a Randomized, Non-inferiority, Double-Blind Trial.
Choi JW; Kim HC; Han J; Jang MJ; Chung JW
Cardiovasc Intervent Radiol; 2024 Mar; 47(3):372-378. PubMed ID: 38147153
[TBL] [Abstract][Full Text] [Related]
2. Idarubicin
Roth GS; Teyssier Y; Abousalihac M; Seigneurin A; Ghelfi J; Sengel C; Decaens T
World J Gastroenterol; 2020 Jan; 26(3):324-334. PubMed ID: 31988592
[TBL] [Abstract][Full Text] [Related]
3. Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study.
Zhao C; Yan H; Xiang Z; Wang H; Li M; Huang M
Invest New Drugs; 2023 Aug; 41(4):617-626. PubMed ID: 37434023
[TBL] [Abstract][Full Text] [Related]
4. Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial.
Guiu B; Chevallier P; Assenat E; Barbier E; Merle P; Bouvier A; Dumortier J; Nguyen-Khac E; Gugenheim J; Rode A; Oberti F; Valette PJ; Yzet T; Chevallier O; Barbare JC; Latournerie M; Boulin M
Radiology; 2019 Jun; 291(3):801-808. PubMed ID: 31038408
[TBL] [Abstract][Full Text] [Related]
5. Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma.
Zheng Z; Ma M; Han X; Li X; Huang J; Zhao Y; Liu H; Kang J; Kong X; Sun G; Sun G; Kong J; Tang W; Shao G; Xiong F; Song J
Acta Biomater; 2023 Feb; 157():337-351. PubMed ID: 36509402
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience.
Favelier S; Boulin M; Hamza S; Cercueil JP; Cherblanc V; Lepage C; Hillon P; Chauffert B; Krausé D; Guiu B
Cardiovasc Intervent Radiol; 2013 Aug; 36(4):1039-46. PubMed ID: 23224215
[TBL] [Abstract][Full Text] [Related]
8. Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial).
Zhu HD; Li X; Sun JH; Zhu X; Liu ZY; Li HL; Lu J; Yan ZP; Shao GL; He XF; Chao M; Lu LG; Zhong BY; Li R; Zhang Q; Teng GJ
Cardiovasc Intervent Radiol; 2024 Mar; 47(3):325-336. PubMed ID: 38413420
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
10. Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin.
Boulin M; Schmitt A; Delhom E; Cercueil JP; Wendremaire M; Imbs DC; Fohlen A; Panaro F; Herrero A; Denys A; Guiu B
Eur Radiol; 2016 Feb; 26(2):601-9. PubMed ID: 26060065
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.
Yoon SM; Ryoo BY; Lee SJ; Kim JH; Shin JH; An JH; Lee HC; Lim YS
JAMA Oncol; 2018 May; 4(5):661-669. PubMed ID: 29543938
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo.
Pinter M; Ulbrich G; Sieghart W; Kölblinger C; Reiberger T; Li S; Ferlitsch A; Müller C; Lammer J; Peck-Radosavljevic M
Radiology; 2015 Dec; 277(3):903-12. PubMed ID: 26131911
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
[TBL] [Abstract][Full Text] [Related]
14. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
[TBL] [Abstract][Full Text] [Related]
15. Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion.
Duan F; Wang EQ; Lam MG; Abdelmaksoud MH; Louie JD; Hwang GL; Kothary N; Kuo WT; Hofmann LV; Sze DY
Radiology; 2016 Feb; 278(2):612-21. PubMed ID: 26334787
[TBL] [Abstract][Full Text] [Related]
16. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
17. Single-Agent versus Combination Doxorubicin-Based Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Single-Blind, Randomized, Phase II Trial.
Liu B; Huang JW; Li Y; Hu BS; He X; Zhao W; Zheng YB; Lu LG
Oncology; 2015; 89(1):23-30. PubMed ID: 25613214
[TBL] [Abstract][Full Text] [Related]
18. A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis of six randomized controlled trials.
Wang H; Cao C; Wei X; Shen K; Shu Y; Wan X; Sun J; Ren X; Dong Y; Liu Y; Zhai B
J Cancer Res Ther; 2020; 16(2):243-249. PubMed ID: 32474508
[TBL] [Abstract][Full Text] [Related]
19. DEB TACE for Intermediate and advanced HCC - Initial Experience in a Brazilian Cancer Center.
Luz JH; Luz PM; Martin HS; Gouveia HR; Levigard RB; Nogueira FD; Rodrigues BC; de Miranda TN; Mamede MH
Cancer Imaging; 2017 Feb; 17(1):5. PubMed ID: 28166821
[TBL] [Abstract][Full Text] [Related]
20. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
